Skip to content

The comparison of effects of ozone and corticosteroids injection in treatment of shoulder inflammatory diseases

The comparison of single session ultrasound-guided ozone and corticosteroid injection in shoulder tendinopathy

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT2016122424572N4
Enrollment
30
Registered
2017-01-27
Start date
2016-10-16
Completion date
Unknown
Last updated
2019-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Shoulder tendinopathy. Impingement syndrome of shoulder

Interventions

Intervention 1: Control group: Ultrasound-guided injection of corticosteroid in the subacromial space with lateral approach. Intervention 2: Intervention group: ULtrasound-guided injection of ozone in

Sponsors

Iran University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 80 Years

Inclusion criteria

Inclusion criteria: Age between 20 and 80 years; Shoulder tendinopathy as positive result of specific test like Neer & Hawkins test; Visual Analogue Scale (VAS) > 4; The willingness of patients to participate in research projects; The absence history of rotator cuff tear, diabetes, coagulation disorders, fractures, rheumatologic diseases, tumors, and infections; Not having shoulder injection in last 3 months; The absence of intraarticular injection contraindications like anticoagulant medications consumption; The absence of corticosteroid and lidocaine injection contraindications such as allergy reaction to these medications and skin infection at the injection site; The absence of ozone injection contraindications such as G6PDD, uncontrolled hyperthyroid, the first 3 months of pregnancy, leukemia.

Exclusion criteria

Exclusion criteria: The willingness of patients to exit from the study at any stage of the project; Noncoming patient for follow-up and evaluation during the follow-up study; Daily use of any type of pain medication by patients for the duration of the study.

Design outcomes

Primary

MeasureTime frame
The severity of symptoms. Timepoint: Zero, two weeks and two months after. Method of measurement: Visual Analog Scale (VAS).;Shoulder Pain and Disability Index. Timepoint: Zero, two weeks and two months after. Method of measurement: SPADI questionnaire.;The severity of symptoms and functional limitations. Timepoint: Zero, two weeks and two months after. Method of measurement: Constant score questionnaire.

Secondary

MeasureTime frame
Side effects. Timepoint: Two weeks and two months after. Method of measurement: Physical examination.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammad Sadegh Khabbaz

Iran University of Medical Sciences

m.sadegh.khabbaz@gmail.com+98 21 8214 1201

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026